Meals to Heal available through Walgreens
NEW YORK — Meals to Heal on Thursday announced that it is working with Walgreens to provide Meals to Heal services to cancer patients and others with chronic conditions in accessing customized nutritional meals and nutrition support services.
“By providing affordable access to Meals to Heal’s convenient, easy-to-use meal delivery solution, we are helping both patients and caregivers maintain wellness and peace of mind during their, and their loved one’s, time of illness,” stated Susan Bratton, CEO, Meals to Heal. “We are thrilled to collaborate with Walgreens, one of the pre-eminent health and wellness companies in the world, and believe that their patient care goals are synergistic with Meals to Heal’s mission of making easier and less stressful the lives of people with chronic conditions and their caregivers.”
Meals to Heal provides home delivery of individually customized meals in the 48 contiguous United States as well as other nutritional resources including telephonic nutritional counseling by a team of oncology-credentialed registered dietitians and safe, evidence-based nutrition information and resources. The company’s meals include heart healthy and diabetic friendly options and are appropriate for patients with cancer and other chronic conditions and who need assistance with meal preparation due to fatigue and lack of energy.
Meals to Heal’s weekly nutrition solutions are available for order on Walgreens.com at a 10% discounted price.
Colgate elects Michael Polk to board of directors
NEW YORK — Colgate-Palmolive announced on Thursday that Michael Polk, president and CEO of Newell Rubbermaid, has been elected to Colgate’s board, effective June 11.
Prior to joining Newell Rubbermaid in 2011, Polk served in various senior leadership roles at Unilever, including president of global foods, home & personal care, and at Kraft Foods, where he was president of Kraft Foods Asia Pacific, president of the biscuits and snacks sector and was a member of the Kraft Foods Management Committee.
FDA approves Valeant’s Jublia
LAVAL, Quebec — Valeant Pharmaceuticals International announced that its subsidiary, Valeant Pharmaceuticals North America, received approval from the Food and Drug Administration for its new drug application for Jublia (efinaconazole 10% topical solution). The drug is the first topical triazole approved for the treatment of onychomycosis of the toenails, the company said.
Onychomycosis is a common nail infection that is undertreated largely due to the limitations of available treatment options, Valeant said. Over-the-counter treatments provide limited efficacy and prescription oral treatments are limited because of drug interactions and other safety concerns.
"Onychomycosis is not only embarrassing and uncomfortable, but also can lead to permanent nail damage and limited mobility in the general population," said American Podiatric Medical Association Executive Director and CEO Glenn B. Gastwirth, DPM. "We welcome the approval of Jublia and encourage people with onychomycosis of the toenails to discuss their condition with their podiatrist or other healthcare professional to find a treatment that’s right for them."
Kraken Pharmaceutical, the licensor and business partner for efinaconazole, agreed to supply Valeant with the final dosage form of Jublia for the U.S. market.